National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 76088 [2020-26152]
Download as PDF
<![CDATA[
76088
Federal Register / Vol. 85, No. 229 / Friday, November 27, 2020 / Notices
• lipid disorder
• metabolic syndrome
Development Stage
• Early stage
Inventors: Kenneth A. Jacobson
(NIDDK), Anna Junker, Elisa Uliassi
(NIDDK), Evgeny Kiselev (NIDDK)
Publications: Junker A,
Balasubramanian R, Ciancetta A, et al.,
Structure-based design of 3-(4-aryl-1H–
1,2,3-triazol-1-yl)-biphenyl derivatives
as P2Y14 receptor antagonists. J. Med.
Chem., 2016, 59:6149¥6168.
Intellectual Property: HHS Reference
No. E–213–2015–0, U.S. Patent No.
10,683,277, issued June 16, 2020, EP
Patent Application 16774825.0, filed
Sept. 23, 2016, Chinese Patent
Application 201680064441.5, filed Sept.
23, 2016.
Licensing Contact: Betty B. Tong,
Ph.D.; 301–451–7836; tongb@
mail.nih.gov. This notice is made in
accordance with 35 U.S.C. 209 and 37
CFR part 404.
Dated: November 19, 2020.
Bei Tong,
Senior Licensing and Patenting Manager,
National Institute of Diabetes and Digestive
and Kidney Diseases, Technology
Advancement Office.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G31,
Rockville, MD 20892, (Virtual Meeting).
Contact Person: Cynthia L. De La Fuente,
Ph.D., Scientific Review Officer, Scientific
Review Program, Division of Extramural
Activities, National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G31,
Rockville, MD 20852, 240–669–2740,
delafuentecl@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: November 20, 2020.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–26152 Filed 11–25–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOUSING AND
URBAN DEVELOPMENT
[Docket No. FR–6236–N–01]
Notice of Certain Operating Cost
Adjustment Factors for 2021
[FR Doc. 2020–26169 Filed 11–25–20; 8:45 am]
BILLING CODE 4140–01–P
Office of the Assistant
Secretary for Housing—Federal Housing
Commissioner, HUD.
ACTION: Notice.
AGENCY:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
jbell on DSKJLSW7X2PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel NIAID SBIR Phase II Clinical
Trial Implementation Cooperative Agreement
(U44 Clinical Trial Required).
Date: December 18, 2020.
Time: 2:30 p.m. to 4:00 p.m.
VerDate Sep<11>2014
19:29 Nov 25, 2020
This notice establishes
operating cost adjustment factors
(OCAFs) for project-based assistance
contracts issued under Section 8 of the
United States Housing Act of 1937 and
renewed under the Multifamily Assisted
Housing Reform and Affordability Act
of 1997 (MAHRA) for eligible
multifamily housing projects having an
anniversary date on or after February 11,
2021. OCAFs are annual factors used to
adjust Section 8 rents renewed under
section 515 or section 524 of MAHRA.
DATES: Applicability Date: February 11,
2021.
FOR FURTHER INFORMATION CONTACT:
Carissa Janis, Program Analyst, Office of
Asset Management and Portfolio
Oversight, Department of Housing and
Urban Development, 451 7th Street SW,
Washington, DC 20410; telephone
number 202–402–2487 (this is not a tollfree number). Hearing- or speechimpaired individuals may access this
number through TTY by calling the tollfree Federal Relay Service at 800–877–
8339.
SUPPLEMENTARY INFORMATION:
SUMMARY:
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Jkt 253001
PO 00000
Frm 00085
Fmt 4703
Sfmt 4703
I. OCAFs
Section 514(e)(2) and section 524(c)(1)
of MAHRA (42 U.S.C. 1437f note)
require HUD to establish guidelines for
the development of OCAFs for rent
adjustments. Sections 524(a)(4)(C)(i),
524(b)(1)(A), and 524(b)(3)(A) of
MAHRA, all of which prescribe the use
of the OCAF in the calculation of
renewal rents, contain similar language.
HUD has therefore used a single
methodology for establishing OCAFs,
which vary among states and territories.
MAHRA gives HUD broad discretion
in setting OCAFs, referring, for example,
in sections 524(a)(4)(C)(i), 524(b)(1)(A),
524(b)(3)(A), and 524(c)(1), to simply
‘‘an operating cost adjustment factor
established by the Secretary.’’ The sole
limitation to this grant of authority is a
specific requirement in each of the
foregoing provisions that application of
an OCAF ‘‘shall not result in a negative
adjustment.’’ Contract rents are adjusted
by applying the OCAF to that portion of
the rent attributable to operating
expenses exclusive of debt service.
The OCAFs provided in this notice
are applicable to eligible projects having
a contract anniversary date of February
11, 2021, or after and were calculated
using the same method as those
published in HUD’s 2020 OCAF notice
published on November 22, 2019 (84 FR
64553). Specifically, OCAFs are
calculated as the sum of weighted
component cost changes for wages,
employee benefits, property taxes,
insurance, supplies and equipment, fuel
oil, electricity, natural gas, and water/
sewer/trash, using publicly available
indices. The weights used in the OCAF
calculations for each of the nine cost
component groupings are set using
current percentages attributable to each
of the nine expense categories. These
weights are calculated in the same
manner as in the November 22, 2019,
notice. Average expense proportions
were calculated using three years of
audited Annual Financial Statements
from projects covered by OCAFs. The
expenditure percentages for these nine
categories have been found to be very
stable over time but using three years of
data increases their stability. The nine
cost component weights were calculated
at the state level, which is the lowest
level of geographical aggregation with
enough projects to permit statistical
analysis. These data were not available
for the Western Pacific Islands, so data
for Hawaii were used as the best
available indicator of OCAFs for these
areas.
The best current price data sources for
the nine cost categories were used in
calculating annual change factors. State-
E:\FR\FM\27NON1.SGM
27NON1
]]>Agencies
[Federal Register Volume 85, Number 229 (Friday, November 27, 2020)]
[Notices]
[Page 76088]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-26152]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel NIAID SBIR Phase II Clinical Trial
Implementation Cooperative Agreement (U44 Clinical Trial Required).
Date: December 18, 2020.
Time: 2:30 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers Lane, Room 3G31,
Rockville, MD 20892, (Virtual Meeting).
Contact Person: Cynthia L. De La Fuente, Ph.D., Scientific
Review Officer, Scientific Review Program, Division of Extramural
Activities, National Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers Lane, Room 3G31,
Rockville, MD 20852, 240-669-2740, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: November 20, 2020.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2020-26152 Filed 11-25-20; 8:45 am]
BILLING CODE 4140-01-P
